Why the study?
Vericiguat improves cardiovascular outcomes in HFrEF, but whether its associated hypotension reflects sustained BP lowering or a distinct hemodynamic safety profile had not been quantitatively characterized.
Comparison
Vericiguat vs placebo
Design
Systematic review and random-effects meta-analysis of randomized placebo-controlled trials with trial sequential analysis
Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis finds vericiguat increases symptomatic hypotension despite minimal blood pressure drop in heart failure, indicating a need for careful titration monitoring.
Purpose Vericiguat, a soluble guanylate cyclase stimulator, improves cardiovascular outcomes in heart failure with reduced ejection fraction (HFrEF). Whether its hypotension reflects sustained blood pressure (BP) lowering or a distinct hemodynamic safety profile has not been quantitatively characterized. Methods We searched PubMed, Embase, Web of Science, CENTRAL, and ClinicalTrials.gov (inception to October 2025; updated August 2026). Randomized placebo-controlled trials of vericiguat in heart failure reporting BP-related outcomes were eligible. Random-effects meta-analysis pooled risk ratios (RR) for hypotension and mean differences (MD) for BP changes; trial sequential analysis (TSA) assessed evidence sufficiency. Results Six trials (12,903 participants) were included. Vericiguat significantly increased symptomatic hypotension (630/6,841 vs. 496/6,011; RR 1.20, 95% CI 1.09–1.32; I 2 = 0%; number needed to harm 68; absolute risk difference 1.47%, 95% CI 0.40%–2.55%) and any hypotension (RR 1.18, 95% CI 1.06–1.32; I 2 = 0%). Trial sequential analysis suggested adequate information under the observed-effect assumption, but was sensitive to the assumed effect size; for symptomatic hypotension the required information size was met only at assumed RRs ≥1.20 and not at 1.15 (16,601 required vs. 12,852 accrued) or 1.10. Vericiguat produced a borderline non-significant SBP reduction (MD −0.80 mmHg, 95% CI −1.61 to 0.01; P = 0.052), no significant DBP difference (MD −0.84, 95% CI −3.53 to 1.85), and no significant increase in hypotension-related discontinuation (RR 1.18, 95% CI 0.94–1.48). An arm-level analysis of 12 vericiguat dose arms across the five trials (6,839 vericiguat and 6,011 placebo) reproduced the excess (RR 1.20, 95% CI 1.04–1.39) and showed no gradient with protocol-defined target dose (RR 1.03 per 1 mg, 95% CI 0.93–1.14). Serious syncope was numerically more frequent (RR 1.32, 95% CI 0.91–1.92). Conclusion In patients with heart failure, vericiguat produces minimal sustained change in blood pressure yet increases symptomatic hypotension by 20% in relative terms (pooled NNH ∼68, 95% CI 39–250), and this risk is neither graded by protocol-defined target dose nor accompanied by a significant increase in treatment discontinuation. These findings suggest that monitoring during dose titration and identifying patients with lower baseline BP, rather than limiting the dose, may better address vericiguat-associated hypotension.
No takes yet. Share an insight, caveat, or question.
Maimaiti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: